2013
DOI: 10.1016/j.cca.2013.03.029
|View full text |Cite
|
Sign up to set email alerts
|

Circulating tumor cells in breast cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
17
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
6
2

Relationship

2
6

Authors

Journals

citations
Cited by 23 publications
(18 citation statements)
references
References 70 publications
1
17
0
Order By: Relevance
“…Disseminated tumor cells in the bone marrow and circulating tumor cells in the blood are rapidly emerging as markers that can predict patient clinical outcome [23] and there are currently a number of interventional clinical trials underway to investigate the benefits of using CTCs as a prognostic marker to determine treatment options [47]. Most current and developing chemotherapeutics focus on reduction in cell proliferation, migration and invasion to determine drug efficacy and thus fail to address the effects of these drugs on free-floating cells that are in circulation.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Disseminated tumor cells in the bone marrow and circulating tumor cells in the blood are rapidly emerging as markers that can predict patient clinical outcome [23] and there are currently a number of interventional clinical trials underway to investigate the benefits of using CTCs as a prognostic marker to determine treatment options [47]. Most current and developing chemotherapeutics focus on reduction in cell proliferation, migration and invasion to determine drug efficacy and thus fail to address the effects of these drugs on free-floating cells that are in circulation.…”
Section: Discussionmentioning
confidence: 99%
“…Nevertheless, many current clinical regimens using traditional chemotherapeutics may fail to eradicate CTCs, which are often quiescent and thus are resistant to chemotherapeutics that target cell division [48]. Even newer targeted tumor-specific small-molecule inhibitors or antibody therapies may be ineffective on CTCs if the CTCs are molecularly different from the primary tumor cells as a result of newly acquired mutations or selective dissemination of clonally heterogeneous tumor cells [23]. For example, microtubule-targeting cytotoxic chemotherapies such as taxanes, which are extremely effective in their anti-proliferative effects on the primary tumor, can significantly increase CTCs in the patients' blood when given prior to surgery [49].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Treatment decisions in non-metastatic BC are based on the characteristics of the primary tumor without considering features of MRD, although the latter is the aim of any adjuvant strategy and molecular profile of MRD may differ from the primary tumor (41). For instance, we previously reported that 71% of patients with ER-positive BC present with ER-negative DTCs in BM; the loss of hormone receptor positivity may contribute to development of endocrine resistance (42).…”
Section: Circulating Tumor Cells In Early Breast Cancermentioning
confidence: 99%
“…Most of these trials (e.g., SWOG0500, CirCe01, TREAT CTC, and DETECT III and IV) are based on immunocytochemical detection of CTCs using the FDA-approved CellSearch system (Veridex, Warren, NJ, USA), a semiautomated antibody-based quantitative technique [88]. Since CTCs are enriched by immunomagnetic beads linked with anti-EpCAM antibodies and detected using antibodies against epithelial antigens, loss of epithelial markers during EMT could make these cells “invisible” to the assay and possibly influence treatment decisions [78, 89].…”
Section: Therapeutic Consequencesmentioning
confidence: 99%